Franklin Resources’s Matinas BioPharma MTNB Stock Holding History

Franklin Resources’s Portfolio MTNB Stock Details MTNB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-200	Closed	-$8K	–	2484
2021 Q2	$8K	Hold	200	–	–	﹤0.01%	1999
2021 Q1	$11K	Hold	200	–	–	﹤0.01%	1960
2020 Q4	$14K	Hold	200	–	–	﹤0.01%	1883
2020 Q3	$8K	Hold	200	–	–	﹤0.01%	1842
2020 Q2	$9K	Hold	200	–	–	﹤0.01%	1660
2020 Q1	$6K	Hold	200	–	–	﹤0.01%	1472
2019 Q4	$23K	Buy	+200	New	+$11.6K	﹤0.01%	1520

Other funds holding MTNB

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

SIG

Sargent Investment Group Bethesda, Maryland $759M AUM 28.58% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

CCM

Courage Capital Management Nashville, Tennessee $70.6M AUM 13.29% 1-Year Est. Return

AWA

Arkadios Wealth Advisors Atlanta, Georgia $6.13B AUM 23.41% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

JEST

JTC Employer Solutions Trustee St Helier, Jersey $1.2B AUM 37.55% 1-Year Est. Return

GCP

GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Franklin Resources's MTNB Position: Q3 2021 in Review

Franklin Resources sold out of Matinas BioPharma (MTNB) in Q3 2021, closing a stake of 200 shares — an estimated $8K sold.

Franklin Resources first reported a position in MTNB in Q4 2019 and held it in 7 quarters. The position peaked at $23K in Q4 2019. 67 funds tracked by Wall St. Rank hold MTNB as of Q3 2021.

Franklin Resources reported no remaining Matinas BioPharma position as of Q3 2021 after selling out during the quarter.
Franklin Resources sold 200 Matinas BioPharma shares in Q3 2021, an estimated $8K.
Franklin Resources first reported a position in Matinas BioPharma in Q4 2019 and held it in 7 quarters.
Franklin Resources's Matinas BioPharma position peaked at $23K in Q4 2019.
67 funds tracked by Wall St. Rank held Matinas BioPharma as of Q3 2021.

Based on Franklin Resources's 13F filing for Q3 2021, filed 12 Nov 2021.